在牛皮咨询中对肥胖的管理
Joana Nicolau1, Anna López-Ferrer2, Pablo de la Cueva3
1Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Interdisciplinary Group in Neurodegeneration, Vascular and Metabolic Diseases, University of Balearic Islands (UIB), Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain.
Dermatology and therapy
|February 2, 2026
概括
肥胖管理对牛皮患者至关重要,影响治疗疗效和健康结果. 本综述强调了生活方式,药物 (GLP-1 RAs,tirezepatide) 和手术选择,为皮肤科医生提供了改善患者护理的指导.
科学领域:
- 皮肤病学和内分泌学
- 代谢综合征研究 代谢综合征研究
背景情况:
- 肥胖影响多达50%的牛皮患者,增加炎症,心血管风险,降低治疗效果.
- 目前的皮肤病学实践缺乏具体的肥胖管理指南,尽管存在显著的重叠和对牛皮的严重程度的影响.
研究的目的:
- 审查生活方式,药理 (GLP-1 RAs,蒂尔泽帕提德) 和皮病患者肥胖的手术策略.
- 为皮肤科医生开发实用算法,在牛皮护理中管理肥胖症,包括分拣和转诊标准.
主要方法:
- 流行病学数据,随机试验,现实研究和指导方针的叙述综合.
- 专注于GLP-1RA和tirzepatide在体重管理中的病理生理学和疗效.
- 开发用于药物治疗升级和多学科转诊的实用算法.
主要成果:
- 没有具体的牛皮肥胖指南存在,但由于肥胖患者治疗反应较差,体重管理至关重要.
- 算法建议生活方式咨询和皮肤病学主导的管理BMI<35. GLP-1 RAs是第一线的,如果需要的话,接着是tirezepatide.
- 减肥手术只适用于BMI≥40或BMI≥35的患者,这些患者有未控制的并发症或之前的治疗失败.
结论:
- 皮肤科医生必须将肥胖评估和以患者为中心的干预措施整合到牛皮管理中.
- 一种结构化,多学科的方法可以显著改善皮肤病,代谢和心血管的结果对于牛皮患者肥胖.
相关概念视频
01:24Obesity
1.3K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.3K
01:21Drug Dosing: Obese Patients
263
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
263
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
282
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
282
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
184
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
184
01:26Tonsillitis II: Management
429
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
429
01:29Impression Management Techniques I: Managing Appearances
218
Appearance is a multidimensional aspect of self-presentation that encompasses observable attributes such as clothing, grooming, speech, and nonverbal behavior. These elements are often strategically managed to align with socially constructed expectations in different settings. For instance, individuals tailor their appearance during job interviews, social gatherings, or athletic events to meet the perceived norms of those environments.Contextual Adaptation and Social SignalsThe research...
218